Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEJ043 ABCP in previously treated EGFR-mutated non-small cell lung cancer
jRCTs031190066Phase 2Completed
- Sponsor
- North East Japan Study Group
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, carboplatin, paclitaxel and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by North East Japan Study Group. Primary endpoint: Progression-free survival. Started Sep 2019; status: completed.
02
Drugs
atezolizumabcarboplatinpaclitaxelbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031190066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190066.